Net Loss: Net loss attributable to common stockholders for the third quarter of 2024 was $ (3.1) million, or $ (1.92) per ...

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...

The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...

Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in ...

The FDA has granted Fast Track designation to PP-007 (PEGylated carboxyhemoglobin, bovine) for the treatment of acute ischemic stroke.

Palatin Technologies, Inc. ( NYSE: PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary ...

Monthly 140 mg erenumab injections are a safe and effective treatment for patients with nonopioid chronic migraine and medication overuse headaches.